{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:32:30Z","timestamp":1789475550785,"version":"build-2803163510"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012533","name":"Minia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bioorg.2026.109972","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:25:47Z","timestamp":1778282747000},"page":"109972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A novel triazole\u2013dithiocarbamate hybrid synergistically enhances cytarabine efficacy and selectivity in anaplastic large cell lymphoma"],"prefix":"10.1016","volume":"178","author":[{"given":"Heba F.","family":"Ashour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa S.A.","family":"Yassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid B.","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda A.A.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed T.","family":"Elhendawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosam A.","family":"Elshihawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2021","key":"10.1016\/j.bioorg.2026.109972_bb0005","first-page":"209","article-title":"GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.109972_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025, CA","volume":"75","author":"Siegel","year":"2025","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.109972_bb0015","doi-asserted-by":"crossref","first-page":"1241532","DOI":"10.3389\/fonc.2023.1241532","article-title":"Updates in pathobiological aspects of anaplastic large cell lymphoma","volume":"13","author":"Wu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0020","doi-asserted-by":"crossref","unstructured":"S.H. Swerdlow, E. Campo, S.A. Pileri, N.L. Harris, H. Stein, R. Siebert, R. Advani, M. Ghielmini, G.A. Salles, A.D. Zelenetz, E.S. Jaffe, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood 127 (2016) 2375\u20132390. doi:https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"10.1016\/j.bioorg.2026.109972_bb0025","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/cancers14071650","article-title":"Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109972_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/cancers10040099","article-title":"Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond","volume":"10","author":"Prokoph","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109972_bb0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.critrevonc.2012.02.005","article-title":"Anaplastic large cell lymphoma, ALK-positive","volume":"83","author":"Ferreri","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0040","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2024014745","article-title":"Pediatric relapsed\/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era","volume":"9","author":"Marks","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.bioorg.2026.109972_bb0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.bioorg.2026.109972_bb0050","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d\u2019Amore","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0055","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390334","article-title":"Frontline Management of Nodal Peripheral T-Cell Lymphomas","author":"Ngu","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.bioorg.2026.109972_bb0060","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.12688\/f1000research.22257.1","article-title":"Treatment approaches in relapsed or refractory peripheral T-cell lymphomas","volume":"9","author":"Foster","year":"2020","journal-title":"F1000Research"},{"key":"10.1016\/j.bioorg.2026.109972_bb0065","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.3390\/cancers13236003","article-title":"Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL","volume":"13","author":"Hare","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109972_bb0070","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0075","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0080","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2147\/OTT.S59795","article-title":"Combination therapy with brentuximab vedotin and cisplatin\/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma","author":"Heidegger","year":"2014","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bioorg.2026.109972_bb0085","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1023\/A:1012501305214","article-title":"Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin\u2019s lymphoma","volume":"12","author":"Machover","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0090","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3390\/cancers13050966","article-title":"Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers","volume":"13","author":"Di Francia","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109972_bb0095","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3892\/ol.2023.13854","article-title":"Effect of arsenic trioxide plus etoposide, solumedrol, high-dose cytarabine and cisplatin chemotherapy on the treatment of relapsed or ref7ractory ALK+ anaplastic large cell lymphoma","volume":"25","author":"Ding","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2026.109972_bb0100","doi-asserted-by":"crossref","first-page":"2016009","DOI":"10.4084\/mjhid.2016.009","article-title":"TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE","volume":"8","author":"Heiblig","year":"2016","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.109972_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2012.00041","article-title":"ALK signaling and target therapy in anaplastic large cell lymphoma","volume":"2","author":"Tabb\u00f3","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112984","article-title":"Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcS\u00e9-crizotinib trial","volume":"191","author":"Brugi\u00e8res","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109972_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase\u2013Positive Lymphoma Patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2026.109972_bb0120","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0125","first-page":"1573","article-title":"Drivers of crizotinib resistance in ALK1 ALCL","volume":"136","author":"Hu","year":"2020","journal-title":"ASH"},{"key":"10.1016\/j.bioorg.2026.109972_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.109972_bb0135","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/ckj\/sfac062","article-title":"Anaplastic lymphoma kinase inhibitors and their effect on the kidney","volume":"15","author":"Bonilla","year":"2022","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.bioorg.2026.109972_bb0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.14740\/jmc3743","article-title":"Long-Term Progression-Free Survival in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patient Treated With Crizotinib","volume":"12","author":"Barsoum","year":"2021","journal-title":"J. Med. Cases"},{"key":"10.1016\/j.bioorg.2026.109972_bb0145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1586\/14737140.2016.1131612","article-title":"Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib","volume":"16","author":"Muller","year":"2016","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.bioorg.2026.109972_bb0150","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1073\/pnas.1019559108","article-title":"Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK","volume":"108","author":"Katayama","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0155","doi-asserted-by":"crossref","first-page":"1139367","DOI":"10.3389\/fcell.2023.1139367","article-title":"Aurora kinases: Generators of spatial control during mitosis","volume":"11","author":"Ali","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: a comprehensive review","volume":"13","author":"Willems","year":"2018","journal-title":"Cell Div"},{"key":"10.1016\/j.bioorg.2026.109972_bb0165","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s12276-021-00635-6","article-title":"Aurora kinase A, a synthetic lethal target for precision cancer medicine","volume":"53","author":"Mou","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.109972_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1541-7786.MCR-06-0208","article-title":"Roles of Aurora Kinases in Mitosis and Tumorigenesis","volume":"5","author":"Fu","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109972_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108633","article-title":"Aurora kinases, emerging critical targets for cancer treatment and related new therapeutic strategies","volume":"163","author":"Chung","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0180","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/modpathol.2012.211","article-title":"Differential expression of aurora-A kinase in T-cell lymphomas","volume":"26","author":"Kanagal-Shamanna","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0185","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1158\/1078-0432.CCR-15-0033","article-title":"Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma","volume":"21","author":"Zullo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109972_bb0190","article-title":"Combined inhibition of aurora kinases and Bcl-xL induces apoptosis through select BH3-only proteins","volume":"299","author":"Li","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0195","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.leukres.2012.10.017","article-title":"Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment","volume":"37","author":"Qi","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bioorg.2026.109972_bb0200","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/DDDT.S74062","article-title":"Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells, Drug Des","author":"Zhou","year":"2015","journal-title":"Devel. Ther."},{"key":"10.1016\/j.bioorg.2026.109972_bb0205","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-9-74","article-title":"Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells","volume":"9","author":"Xu","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.109972_bb0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2009.08.011","article-title":"Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways","volume":"79","author":"Li","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0215","series-title":"Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma","author":"Kumar","year":"2024"},{"key":"10.1016\/j.bioorg.2026.109972_bb0220","first-page":"969","article-title":"Aurora kinase inhibitor VX-680 enhances sensitivity of esophageal squamous cell carcinoma cells to cisplatin chemotherapy, Anticancer","volume":"32","author":"Kou","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109972_bb0225","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/ijc.27579","article-title":"Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism","volume":"131","author":"Kelly","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109972_bb0230","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-11-2413","article-title":"Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma","volume":"18","author":"Mahadevan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109972_bb0235","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1158\/1535-7163.MCT-09-0609","article-title":"MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel","volume":"9","author":"Shimomura","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109972_bb0240","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s10637-015-0306-7","article-title":"A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors","volume":"34","author":"Amin","year":"2016","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bioorg.2026.109972_bb0245","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/13543780902806392","article-title":"Aurora kinase inhibitors in preclinical and clinical testing","volume":"18","author":"Cheung","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.109972_bb0250","series-title":"Peripher","article-title":"Novel Aurora Kinase Inhibitor-Based Combination Therapies for PTCL","author":"Tenneti","year":"2019"},{"key":"10.1016\/j.bioorg.2026.109972_bb0255","article-title":"Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0260","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.humpath.2006.02.020","article-title":"Intrinsic apoptotic pathway in anaplastic large cell lymphoma","volume":"37","author":"Oyarzo","year":"2006","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0265","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/blood-2007-04-060715","article-title":"Pathobiology of ALK+ anaplastic large-cell lymphoma","volume":"110","author":"Amin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109972_bb0270","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/leu.2009.161","article-title":"Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma","volume":"23","author":"Eckerle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109972_bb0275","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/leu.2014.347","article-title":"The European T-cell Lymphoma Study Group, A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation","volume":"29","author":"Abate","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109972_bb0280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.freeradbiomed.2015.02.027","article-title":"The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines","volume":"84","author":"Carnesecchi","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bioorg.2026.109972_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108109","article-title":"Genetic alterations and oxidative stress in T cell lymphomas","volume":"236","author":"Kumar","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109972_bb0290","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.2147\/OTT.S107957","article-title":"ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2\/STAT3 pathway","volume":"9","author":"Jiang","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bioorg.2026.109972_bb0295","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1158\/0008-5472.CAN-06-2272","article-title":"Aurora-A Regulation of Nuclear Factor-\u03baB Signaling by Phosphorylation of I\u03baB\u03b1","volume":"67","author":"Briassouli","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109972_bb0300","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbrc.2006.11.004","article-title":"Aurora kinase inhibition downregulates NF-\u03baB and sensitises tumour cells to chemotherapeutic agents","volume":"352","author":"Sun","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2026.109972_bb0305","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cels.2019.01.005","article-title":"ROS and Oxidative Stress Are Elevated in Mitosis during Asynchronous Cell Cycle Progression and Are Exacerbated by Mitotic Arrest","volume":"8","author":"Patterson","year":"2019","journal-title":"Cell Syst."},{"key":"10.1016\/j.bioorg.2026.109972_bb0310","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12915-016-0335-5","article-title":"Phosphorylation-dependent regulation of ALDH1A1 by Aurora kinase A: insights on their synergistic relationship in pancreatic cancer","volume":"15","author":"Wang","year":"2017","journal-title":"BMC Biol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0315","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1053\/j.seminoncol.2015.09.022","article-title":"Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress","volume":"42","author":"Falchook","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00278","article-title":"Aurora Kinase Inhibitors: Current Status and Outlook","volume":"5","author":"Bavetsias","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0325","doi-asserted-by":"crossref","first-page":"0747","DOI":"10.34133\/research.0747","article-title":"Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications","volume":"8","author":"Baldi","year":"2025","journal-title":"Research"},{"key":"10.1016\/j.bioorg.2026.109972_bb0330","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","article-title":"VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo","volume":"10","author":"Harrington","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.109972_bb0335","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/1535-7163.MCT-09-0041","article-title":"GSK1070916, a potent Aurora B\/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models","volume":"8","author":"Hardwicke","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109972_bb0340","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109972_bb0345","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.22222","article-title":"Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy","volume":"8","author":"Islam","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109972_bb0350","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1110\/ps.036590.108","article-title":"Modulation of kinase-inhibitor interactions by auxiliary protein binding: Crystallography studies on Aurora A interactions with VX-680 and with TPX2","volume":"17","author":"Zhao","year":"2008","journal-title":"Protein Sci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0355","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.7832","article-title":"Exploration of the selective binding mechanism of protein kinase Aurora A selectivity via a comprehensive molecular modeling study","volume":"7","author":"Zhang","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.bioorg.2026.109972_bb0360","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00018-012-1073-7","article-title":"Aurora A kinase (AURKA) in normal and pathological cell division","volume":"70","author":"Nikonova","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0365","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.drudis.2010.12.003","article-title":"Aurora-A kinase inhibitor scaffolds and binding modes","volume":"16","author":"Yan","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2026.109972_bb0370","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s10637-012-9798-6","article-title":"Aurora kinase inhibitors: Progress towards the clinic","volume":"30","author":"Kollareddy","year":"2012","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bioorg.2026.109972_bb0375","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1021\/jm049076m","article-title":"Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase Inhibition","volume":"48","author":"Fancelli","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0380","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1074\/jbc.M111.312090","article-title":"Activation of Aurora-A Kinase by Protein Partner Binding and Phosphorylation Are Independent and Synergistic","volume":"287","author":"Dodson","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00285","article-title":"A Cell Biologist\u2019s Field Guide to Aurora Kinase Inhibitors","volume":"5","author":"De Groot","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0390","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1021\/jm801270e","article-title":"Structure-Based Drug Design of Novel Aurora Kinase A Inhibitors: Structural Basis for Potency and Specificity","volume":"52","author":"Coumar","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0395","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1039\/C2MB25217A","article-title":"Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity","volume":"8","author":"Yang","year":"2012","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.bioorg.2026.109972_bb0400","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1042\/BJ20091530","article-title":"Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design","volume":"427","author":"Dodson","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2026.109972_bb0405","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/cb100053q","article-title":"Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237","volume":"5","author":"Sloane","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0410","doi-asserted-by":"crossref","first-page":"eaax2713","DOI":"10.1126\/scisignal.aax2713","article-title":"Aurora A regulation by reversible cysteine oxidation reveals evolutionarily conserved redox control of Ser\/Thr protein kinase activity","volume":"13","author":"Byrne","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bioorg.2026.109972_bb0415","doi-asserted-by":"crossref","first-page":"eabb6707","DOI":"10.1126\/scisignal.abb6707","article-title":"Redox priming promotes Aurora A activation during mitosis","volume":"13","author":"Lim","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bioorg.2026.109972_bb0420","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.apsb.2023.03.013","article-title":"Emerging roles of Aurora-A kinase in cancer therapy resistance","volume":"13","author":"Zheng","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.109972_bb0425","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bioorg.2017.01.010","article-title":"Medicinal attributes of 1,2,3-triazoles: Current developments","volume":"71","author":"Dheer","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0430","first-page":"17","article-title":"Strategic Fusion: 1,2,3-Triazole Hybrids as Next-Generation Dual\/Multi-Targeted Anticancer Agents \u2013 A 2025 Perspective","volume":"10","author":"Ashour","year":"2026","journal-title":"Rec. Pharm. Biomed. Sci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.864286","article-title":"Triazoles and Their Derivatives: Chemistry, Synthesis, and Therapeutic Applications","volume":"9","author":"Matin","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0440","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11094-025-03390-4","article-title":"Prospects for Using 1,2,3-Triazole Derivatives in Medicinal Chemistry","volume":"59","author":"Kukov","year":"2025","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.bioorg.2026.109972_bb0445","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1016\/j.bmc.2019.07.005","article-title":"1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview","volume":"27","author":"Bozorov","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0450","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.3390\/molecules25163576","article-title":"1,4-Disubstituted 1,2,3-Triazoles as Amide Bond Surrogates for the Stabilisation of Linear Peptides with Biological Activity","volume":"25","author":"Re\u010dnik","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109972_bb0455","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2533\/chimia.2013.262","article-title":"1,2,3-Triazoles as Amide-bond Surrogates in Peptidomimetics","volume":"67","author":"Valverde","year":"2013","journal-title":"CHIMIA"},{"key":"10.1016\/j.bioorg.2026.109972_bb0460","doi-asserted-by":"crossref","first-page":"20812","DOI":"10.1039\/D1RA03356E","article-title":"1,2,3-Triazole framework: a strategic structure for C\u2013H\u22efX hydrogen bonding and practical design of an effective Pd-catalyst for carbonylation and carbon\u2013carbon bond formation","volume":"11","author":"Mohammadsaleh","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.109972_bb0465","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1021\/acs.jmedchem.4c00652","article-title":"Triazoles in medicinal chemistry: physicochemical properties, bioisosterism, and application","volume":"67","author":"Guan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0470","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.bmc.2016.03.042","article-title":"Design, synthesis, and evaluation of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives as Aurora kinase inhibitors","volume":"24","author":"Jeong","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0475","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s00044-023-03132-9","article-title":"Synthesis, in-silico based virtual screening,anti-cancer potential of novel1,2,3-triazole-thiadiazole hybrid derivatives as Aurora kinase A (ARK-A) and Extracellular regulated kinase 2 (ERK2) dual inhibitors","volume":"32","author":"Bontha","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.109972_bb0480","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3390\/ijms23031317","article-title":"The Versatility in the Applications of Dithiocarbamates","volume":"23","author":"Ajiboye","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102092","article-title":"The revival of dithiocarbamates: from pesticides to innovative medical treatments","volume":"24","author":"Kaul","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.bioorg.2026.109972_bb0490","doi-asserted-by":"crossref","first-page":"243","DOI":"10.12688\/f1000research.109553.1","article-title":"A review of the therapeutic properties of dithiocarbamates","volume":"11","author":"Tella","year":"2022","journal-title":"F1000Research"},{"key":"10.1016\/j.bioorg.2026.109972_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104346","article-title":"An insight into medicinal attributes of dithiocarbamates: Bird\u2019s eye view","volume":"105","author":"Shinde","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0500","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1021\/jm0508888","article-title":"Structure\u2212 activity study of brassinin derivatives as indoleamine 2, 3-dioxygenase inhibitors","volume":"49","author":"Gaspari","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0505","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.tiv.2014.04.002","article-title":"Brassinin and its derivatives as potential anticancer agents","volume":"28","author":"Chripkova","year":"2014","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.bioorg.2026.109972_bb0510","doi-asserted-by":"crossref","first-page":"10877","DOI":"10.3390\/molecules190810877","article-title":"ROS-Dependent Antiproliferative Effect of Brassinin Derivative Homobrassinin in Human Colorectal Cancer Caco2 Cells","volume":"19","author":"Kello","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109972_bb0515","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.bjc.6600078","article-title":"Thiram inhibits angiogenesis and slows the development of experimental tumours in mice","volume":"86","author":"Marikovsky","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109972_bb0520","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40360-023-00655-0","article-title":"Thiram, an inhibitor of 11\u00df-hydroxysteroid dehydrogenase type 2, enhances the inhibitory effects of hydrocortisone in the treatment of osteosarcoma through Wnt\/\u03b2-catenin pathway","volume":"24","author":"Zhang","year":"2023","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0525","article-title":"Anticancer Effects of Disulfiram: A Systematic Review of in Vitro","author":"Wang","year":"2021","journal-title":"Animal, and Human Studies"},{"key":"10.1016\/j.bioorg.2026.109972_bb0530","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3390\/pharmaceutics15061567","article-title":"Advancing Cancer Therapy with Copper\/Disulfiram Nanomedicines and Drug Delivery Systems","volume":"15","author":"Kang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.109972_bb0535","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.2174\/1381612825666190816233755","article-title":"An updated review of disulfiram: molecular targets and strategies for cancer treatment","volume":"25","author":"Yang","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bioorg.2026.109972_bb0540","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.exphem.2003.11.008","article-title":"HTLV-I Tax protein inhibits apoptosis induction but not G1 arrest by pyrrolidinedithiocarbamate, an anti-oxidant, in adult T cell leukemia cells","volume":"32","author":"Arima","year":"2004","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0545","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.exphem.2015.06.303","article-title":"A new ATL xenograft model and evaluation of pyrrolidine dithiocarbamate as a potential ATL therapeutic agent","volume":"43","author":"Nakamura","year":"2015","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0550","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1016\/j.bmcl.2011.03.029","article-title":"Synthesis and in vitro antitumor activity of new butenolide-containing dithiocarbamates","volume":"21","author":"Wang","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109972_bb0555","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejmech.2015.02.030","article-title":"Discovery and optimization of novel dual dithiocarbamates as potent anticancer agents","volume":"93","author":"Li","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0560","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbrc.2015.01.102","article-title":"LRD-22, a novel dual dithiocarbamatic acid ester, inhibits Aurora-A kinase and induces apoptosis and cell cycle arrest in HepG2 cells","volume":"458","author":"Wang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2026.109972_bb0565","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1021\/jm401002r","article-title":"Triazole\u2013dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration","volume":"56","author":"Zheng","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0570","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejmech.2013.03.058","article-title":"Design, synthesis and antiproliferative activity studies of novel 1,2,3-triazole\u2013dithiocarbamate\u2013urea hybrids","volume":"64","author":"Duan","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0575","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molstruc.2008.05.028","article-title":"One-pot synthesis and the fluorescent behavior of 4-acetyl-5-methyl-1,2,3-triazole regioisomers","volume":"892","author":"Kamalraj","year":"2008","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109972_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112062","article-title":"1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226","volume":"189","author":"Ashour","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0585","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1055\/s-0029-1216875","article-title":"Synthesis of 2, 1-benzisoxazoles by nucleophilic substitution of hydrogen in nitroarenes activated by the azole ring","volume":"2009","author":"Pokhodylo","year":"2009","journal-title":"Synthesis"},{"key":"10.1016\/j.bioorg.2026.109972_bb0590","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2012-12-472027","article-title":"Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma","volume":"122","author":"Matasar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109972_bb0595","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18433\/J30C7D","article-title":"Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations","volume":"14","author":"Chidambaram","year":"2011","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0600","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2026.109972_bb0605","article-title":"Uchil, Analysis of cell viability by the MTT assay","volume":"2018","author":"Kumar","year":"2018","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.bioorg.2026.109972_bb0610","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/s41598-023-43274-9","article-title":"Rational design and characterization of cell-selective antimicrobial peptides based on a bioactive peptide from Crocodylus siamensis hemoglobin","volume":"13","author":"Sosiangdi","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109972_bb0615","doi-asserted-by":"crossref","first-page":"73","DOI":"10.56499\/jppres21.1180_10.1.73","article-title":"Induction of apoptosis by Ruta chalepensis L. essential oil in human breast cancer cells (MCF-7)","volume":"10","author":"Althaher","year":"2022","journal-title":"J. Pharm. Pharmacogn. Res."},{"key":"10.1016\/j.bioorg.2026.109972_bb0620","doi-asserted-by":"crossref","first-page":"060","DOI":"10.7324\/JAPS.2020.102010","article-title":"Synthesis of new boron containing compound (CCB-2) based on curcumin structure and its cytotoxic effect against cancer cells","volume":"10","author":"Meiyanto","year":"2020","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0625","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1038\/s41467-022-33672-4","article-title":"Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors","volume":"13","author":"Chou","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109972_bb0630","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109972_bb0635","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00295","article-title":"Aurora-A Kinase as a Promising Therapeutic Target in Cancer","volume":"5","author":"D\u2019Assoro","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0640","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.3390\/ijms24054487","article-title":"A Brief Review on Chemoresistance; Targeting Cancer Stem Cells as an Alternative Approach","volume":"24","author":"Toledo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0645","series-title":"Drug Resist","first-page":"137","article-title":"Oxidative stress and drug resistance in cancer","author":"Trachootham","year":"2009"},{"key":"10.1016\/j.bioorg.2026.109972_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101953","article-title":"Reactive oxygen species produced by altered tumor metabolism impacts cancer stem cell maintenance","volume":"44","author":"Tuy","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0655","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41388-021-02105-9","article-title":"Disrupted mitochondrial homeostasis coupled with mitotic arrest generates antineoplastic oxidative stress","volume":"41","author":"Hao","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.109972_bb0660","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3390\/cancers16112031","article-title":"Influence of Aldehyde Dehydrogenase Inhibition on Stemness of Endometrial Cancer Stem Cells","volume":"16","author":"Serambeque","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109972_bb0665","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109972_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173919","article-title":"Synergistic potential of dual andrographolide and melatonin targeting of metastatic colon cancer cells: Using the Chou-Talalay combination index method","volume":"897","author":"Banerjee","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109972_bb0675","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.3390\/ijms25147938","article-title":"Synergistic Enhancement of Chemotherapy-Induced Cell Death and Antitumor Efficacy against Tumoral T-Cell Lymphoblasts by IMMUNEPOTENT CRP","volume":"25","author":"Rivera-Lazar\u00edn","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0680","doi-asserted-by":"crossref","first-page":"11018","DOI":"10.18632\/oncotarget.6920","article-title":"Aldehyde dehydrogenase 1A1 in stem cells and cancer","volume":"7","author":"Tomita","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109972_bb0685","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41419-025-07653-6","article-title":"Mechanisms of chemotherapy failure in refractory\/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolism","volume":"16","author":"Yeon Chae","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.109972_bb0690","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1038\/s41388-021-01711-x","article-title":"Aurora-A kinase oncogenic signaling mediates TGF-\u03b2-induced triple-negative breast cancer plasticity and chemoresistance","volume":"40","author":"Jalalirad","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.109972_bb0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2025.14959","article-title":"ALDH1A1 in breast cancer: A prospective target to overcome therapy resistance (Review)","volume":"29","author":"Varisli","year":"2025","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2026.109972_bb0700","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1811158115","article-title":"Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states","volume":"115","author":"Lake","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.109972_bb0705","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/ci800293n","article-title":"Validation of molecular docking programs for virtual screening against dihydropteroate synthase","volume":"49","author":"Hevener","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2026.109972_bb0710","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1021\/jm050362n","article-title":"A critical assessment of docking programs and scoring functions","volume":"49","author":"Warren","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0715","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.bioorg.2026.109972_bb0720","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1021\/cr040426m","article-title":"Molecular dynamics: survey of methods for simulating the activity of proteins","volume":"106","author":"Adcock","year":"2006","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.109972_bb0725","first-page":"3213","article-title":"A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2","volume":"39","author":"Islam","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.109972_bb0730","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109972_bb0735","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109972_bb0740","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2026.109972_bb0745","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat. Rev. Cancer"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:50:01Z","timestamp":1779699001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826005080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":149,"alternative-id":["S0045206826005080"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109972","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel triazole\u2013dithiocarbamate hybrid synergistically enhances cytarabine efficacy and selectivity in anaplastic large cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109972"}}